A Study of Remternetug (LY3372993) in Healthy Chinese Participants

This Phase 1 study evaluates the safety, tolerability, and how the body processes remternetug (LY3372993) — an investigational monoclonal antibody that targets amyloid plaques in the brain (like those associated with Alzheimer's disease) — when injected under the skin in healthy Chinese adults. The study is specifically designed for Chinese participants to gather data relevant to this population. Healthy adults of Chinese descent (all four grandparents must be of Chinese origin and born in China) with a BMI between 18 and 28, no significant health conditions, and no family history of early-onset Alzheimer's disease may be eligible; only participants who are not capable of becoming pregnant (or are assigned male at birth) will be enrolled. Participation involves a single subcutaneous injection, blood tests, ECGs, brain MRI, and follow-up visits over approximately 25 weeks. This summary was generated with AI assistance and is intended to help patients understand the study in plain language.